Upload Avatar (500 x 500)
Liang Weng
Basic Medical Sciences
Peking University
Beijing
Language: English, Chinese, Japanese
Metabolic Reprogramming
Immune Microenvironment
Disease Progression
Tumors
Lung Cancer
Immunotherapy
Resistance Mechanisms
Post-Translational Modifications
Subtype Transition
Diagnostic Markers
Areas of Focus
- Metabolic reprogramming and immune microenvironment remodeling in disease progression, especially in tumors
- Mechanisms of lung cancer occurrence and resistance to immunotherapy
Work Experience
- 2013-2014 - Postdoctoral Fellow, Department of Pathology, Nagoya University, Japan
- 2014-2018 - Designated Assistant Professor, Department of Pathology, Nagoya University, Japan
- 2018-2024 - Associate Investigator, Xiangya Hospital, Central South University, China
- 2024-present - Assistant Professor (Tenure-Track), Associate Investigator, Department of Pathology, School of Basic Medical Science, Peking University Health Science Center, China
Academic Background & Achievements
- 2005 B.S. in Basic Medical Science: Peking University
- 2009 M.S. in Geriatrics: Beijing Institute of Geriatrics, National Health Commission
- 2013 Ph.D. in Pathology: Nagoya University
Publications
- Endothelial RIPK1 protects artery bypass graft against arteriosclerosis by regulating SMC growth, Liang Weng, 2023
- E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC, Liang Weng, 2023
- Regulation of cargo-selective endocytosis by dynamin 2 GTPase-activating protein girdin, Liang Weng, 2014
- Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex, Liang Weng, 2018
- Identification of tumour-infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma, Liang Weng, 2023
- Assessment of causal effects of visceral adipose tissue on risk of cancers: a Mendelian randomization study, Liang Weng, 2022
- Paradoxical effects of DNA tumor virus oncogenes on epithelium-derived tumor cell fate during tumor progression and chemotherapy response, Liang Weng, 2021
- SLC3A2 Promotes Tumor Associated Macrophage Polarization via Metabolic Reprogramming in Lung Cancer, Liang Weng, 2023
- Girdin Promotes Tumorigenesis and Chemoresistance in Lung Adenocarcinoma by Interacting with PKM2, Liang Weng, 2022
- Dvl2 facilitates the coordination of NF-κB and Wnt signaling to promote colitis-associated colorectal progression, Liang Weng, 2022
